Showing 7,621 - 7,640 results of 7,713 for search '"the United States"', query time: 0.15s Refine Results
  1. 7621
  2. 7622
  3. 7623
  4. 7624

    Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era by Ayotola Fatola, Michael D. Evans, Jenna Brown, Elizabeth Davis, Andrew Johnson, Ana G. Antun, Andrew M. Farland, Ryan Woods, Ara Metjian, Yara A. Park, Gustaaf de Ridder, Briana Gibson, Raj S. Kasthuri, Darla K. Liles, Susan Eubanks, Frank Akwaa, Todd Clover, Lisa Baumann Kreuziger, J. Evan Sadler, Meera Sridharan, Ronald S. Go, Keith R. McCrae, Harsh Vardhan Upreti, Ming Y. Lim, Nicole K. Kocher, Radhika Gangaraju, X. Long Zheng, Jay S. Raval, Camila Masias, Spero R. Cataland, Marshall Mazepa, Shruti Chaturvedi

    Published 2025-01-01
    “…Rituximab is frequently administered to prevent relapses, but whether the durability of rituximab effect is maintained with subsequent treatment courses has not been studied. Using the United States Thrombotic Microangiopathy Consortium (USTMA) retrospective iTTP registry, we evaluated clinical relapse-free survival (RFS) with subsequent courses of rituximab treatment in multiply relapsing patients. …”
    Get full text
    Article
  5. 7625
  6. 7626
  7. 7627
  8. 7628

    Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study by Bruno Fattizzo, Alfredo Marchetti, Alessandro Bosi, Carmelo Gurnari, Juri Alessandro Giannotta, Giacinto Luca Pedone, Elena Rossi, Valentina Carrai, Andrea Guido, Filippo Brioschi, Monica Carpenedo, Monica Crugnola, Domenica Caramazza, Livia Leuzzi, Monia Marchetti, Gabriele Merati, Simona Malato, Fabrizio Vianello, Andrea Patriarca, Hussein Awada, Marta Bortolotti, Marta Canzi, Niccolò Bolli, Marco Capecchi, Frederick Chen, Andrea Artoni, Jaroslaw P. Maciejewski, Wilma Barcellini

    Published 2025-02-01
    “…In this multicentric retrospective observational study, we enrolled 167 adult patients with ITP, followed at 13 centers in Italy, United Kingdom, and the United States. Patients underwent NGS evaluation after a median of 3.6 years from ITP onset, and 83% had received at least 1 therapy line, for a median of 2 lines (range, 0-9); 51 of 167 patients (30%) had at least 1 mutation. …”
    Get full text
    Article
  9. 7629
  10. 7630

    Development and validation of a screening tool for sepsis without laboratory results in the emergency department: a machine learning studyResearch in context by Shan Jiang, Shuai Dai, Yulin Li, Xianlong Zhou, Cheng Jiang, Cong Tian, Yana Yuan, Chengwei Li, Yan Zhao

    Published 2025-02-01
    “…The external validation was performed with the Medical Information Mart for Intensive Care IV ED database (United States), and adopted the same inclusion and exclusion criteria. …”
    Get full text
    Article
  11. 7631
  12. 7632

    Evolution of Green Technology, Technology Gap and International Trade A Comparative Study of Developing and Developed Countries by Mehrnoosh Patimar, Zahra Zamani

    Published 2024-12-01
    “…Methodology This research aims to investigate the technology gap and green technology and its effects on international trade between developed countries (Japan, South Korea, France, Germany, the United States, China) and developing countries (Iran, Turkey, Azerbaijan, Tajikistan, Pakistan, Kazakhstan, Kyrgyzstan, Uzbekistan). …”
    Get full text
    Article
  13. 7633
  14. 7634
  15. 7635

    Mesenchymal Progenitor Cells and Their Orthopedic Applications: Forging a Path towards Clinical Trials by Deana S. Shenaq, Farbod Rastegar, Djuro Petkovic, Bing-Qiang Zhang, Bai-Cheng He, Liang Chen, Guo-Wei Zuo, Qing Luo, Qiong Shi, Eric R. Wagner, Enyi Huang, Yanhong Gao, Jian-Li Gao, Stephanie H. Kim, Ke Yang, Yang Bi, Yuxi Su, Gaohui Zhu, Jinyong Luo, Xiaoji Luo, Jiaqiang Qin, Russell R. Reid, Hue H. Luu, Rex C. Haydon, Tong-Chuan He

    Published 2010-01-01
    “…A review of www.ClinicalTrials.gov of the United States National Institute of Health was performed, and ongoing clinical trials will be discussed in addition to the sentinel preclinical studies that paved the way for human investigations.…”
    Get full text
    Article
  16. 7636
  17. 7637

    The impact of preoperative venous thromboembolism on patients undergoing TURBT: Perioperative outcomes and healthcare costs from US insurance claims data by Anas S. Tresh, Francesco Del Giudice, Shufeng Li, Satvir Basran, Ettore De Berardinis, Dalila Carino, Valerio Santarelli, Bernardo Rocco, Maria Chiara Shighinolfi, Roman Mayr, Matteo Ferro, Riccardo Autorino, Gabriele Bignante, Felice Crocetto, Biagio Barone, Renate Pichler, José Daniel Subiela, Jorge Caño Velasco, Marco Moschini, Andrea Mari, Andrea Gallioli, Francesco Soria, Simone Albisinni, Wojciech Krajewski, Jan Łaszkiewicz, Łukasz Nowak, Tomasz Szydełko, Benjamin Challacombe, Rajesh Nair, Benjamin I. Chung

    Published 2025-01-01
    “…Abstract Objectives To assess the impact of a positive history of venous thromboembolism (VTE) on perioperative outcomes, including length of in‐hospital stay, readmission rates, 90‐day postoperative complications, and healthcare costs in bladder cancer (BCa) patients undergoing transurethral resection of bladder tumour (TURBT) in the United States. Patients and Methods Patients aged ≥18 years with a BCa diagnosis undergoing TURBT were identified in the Merative® Marketscan® Research de‐identified databases between 2007 and 2021. …”
    Get full text
    Article
  18. 7638
  19. 7639
  20. 7640